Fabior is an acne treatment drug owned by Mayne Pharma. The active ingredient in Fabior is tazarotene, which contributes to its effectiveness. This drug was first approved for market use on May 11, 2012.
The generic version of Fabior isn't available until the expiry date of the last patent, which is on February 24, 2030. Therefore, Fabior generic may be released after this date.
Fabior is used for the topical treatment of acne vulgaris in patients aged 12 years or older. It comes in an aerosol, foam; topical dosage form that contains tazarotene.
Fabior is backed by 3 drug patents, none of which has expired. These patents expiring on February 24, 2030, bear titles 'Topical foam composition.' The details of the patents regarding the possibility of Fabior generic are given below: